You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu

News

Orbsen announces results from Nephstrom trial

Orbsen Therapeutics – a company which focuses on stromal cell immunotherapies – has announced positive results from the EU Horizon 2020-funded Nephstrom clinical trial for diabetic kidney disease (DKD).